Joseph M. Unger, PhD, on the Impact of NCI-Sponsored Treatment Trials
ESMO Congress 2021
Joseph M. Unger, PhD, of Fred Hutchinson Cancer Research Center, discusses findings from his study of the National Cancer Institute’s Clinical Trials Network, which has conducted publicly funded cancer research for more than 50 years. The substantial gains in life years for patients with cancer, he says, supports the critical role of government-sponsored cancer research (Abstract 1503O).
The ASCO Post Staff
Helena M. Earl, MBBS, PhD, of the University of Cambridge, discusses an individual patient data meta-analysis of noninferiority randomized clinical trials to determine whether a duration of less than the standard of 12 months of adjuvant trastuzumab is noninferior for treatment outcomes in patients with HER2-positive early breast cancer (Abstract LBA11).
The ASCO Post Staff
Robin Cornelissen, MD, PhD, of Erasmus University in Rotterdam, discusses phase II findings from the ZENITH20-4 study, which explored the question of whether poziotinib could benefit patients whose newly diagnosed non–small cell lung cancer harbors EGFR and HER2 exon 20 mutations. Potentially, this novel tyrosine kinase inhibitor may fill an unmet medical need (Abstract LBA46).
The ASCO Post Staff
Jason J. Luke, MD, of UPMC Hillman Cancer Center, discusses phase III results showing that adjuvant pembrolizumab for patients with resected stage IIB and IIC melanoma decreased the risk of disease recurrence or death by 35% compared with placebo. It was also associated with significantly prolonged recurrence-free survival (Abstract LBA3).
The ASCO Post Staff
Gerhardt Attard, MD, PhD, of The Royal Marsden NHS Foundation Trust, discusses findings that show 2 years of abiraterone acetate plus prednisolone-based treatment improves metastasis-free and overall survival in men with high-risk nonmetastatic prostate cancer. The data suggest this combination regimen might be considered a new standard of care (Abstract LBA4).
The ASCO Post Staff
Thomas Powles, MD, PhD, of Queen Mary University of London, discusses phase II results from the NORSE study, which showed that the kinase inhibitor erdafitinib plus the monoclonal antibody cetrelimab produced meaningful responses in cisplatin-ineligible patients with first-line metastatic or locally advanced urothelial carcinoma and fibroblast growth factor receptor (FGFR) alterations (Abstract LBA27).
